Loading
Life sciences · Journal article
Langenbeck S Archives of Surgery · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Neoadjuvant therapy (NAT) is standard care for borderline resectable and locally advanced pancreatic cancer (PC). While minimally invasive surgery (MIS) is increasingly utilized post-NAT, surgical decision-making and technical feasibility remain debated. This review evaluates current evidence on patient selection, surgical timing, and technical strategies for MIS following NAT. A structured search was conducted in PubMed/MEDLINE and OpenAlex, supplemented by a manual search of landmark trials, consensus guidelines, and technical studies focusing on MIS following NAT for PC. Data on oncological radicality, perioperative outcomes, and vascular reconstruction were synthesized. Patient selection requires multidisciplinary evaluation integrating radiographic response and CA19-9 normalization. Post-NAT laparoscopic and robotic pancreatic resections achieve R0 resection rates, lymph node yields, and overall survival comparable to open surgery, with added benefits of reduced overall morbidity and shorter hospital stays in selected cohorts. Key technical approaches facilitating MIS in this setting include selective staging laparoscopy, artery-first dissection to establish resectability, arterial divestment preserving main vessels, standardized portal/superior mesenteric vein reconstruction, and adaptive anastomotic techniques tailored to therapy-induced fibrotic pancreatic parenchyma. MIS following NAT is safe, feasible, and oncologically sound when performed by experienced surgical teams in high-volume centers. Prospective studies and molecular response markers are warranted to further refine patient selection.